Liposomal amphotericin B treatment of Old World cutaneous and mucosal leishmaniasis: A literature review
Old World cutaneous and mucosal leishmaniasis is a potentially serious disease. Systemic treatment approaches with pentavalent antimonials, liposomal amphotericin B, fluconazole and miltefosine are increasingly used despite the absence of supportive evidence − to date, no prospective clinical trials...
Gespeichert in:
| Veröffentlicht in: | Acta tropica 2018-06, Vol.182, p.246-250 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 250 |
|---|---|
| container_issue | |
| container_start_page | 246 |
| container_title | Acta tropica |
| container_volume | 182 |
| creator | Mosimann, Vincent Neumayr, Andreas Paris, Daniel H. Blum, Johannes |
| description | Old World cutaneous and mucosal leishmaniasis is a potentially serious disease. Systemic treatment approaches with pentavalent antimonials, liposomal amphotericin B, fluconazole and miltefosine are increasingly used despite the absence of supportive evidence − to date, no prospective clinical trials have been conducted for systemic treatment of these diseases.
We performed a literature search to delineate the contemporary evidence for the use of liposomal amphotericin B, and found that although cure rates of 17/20 (85%) were achieved in immune competent patients with Old World cutaneous leishmaniasis and cure rates of 10/13 (77%) for Old World mucosal leishmaniasis due to L. infantum, the available data is highly limited with high variation in total treatment dosages. The presented findings reflect a lack of consensus on the optimal treatment dosage and on the schedule of application. |
| doi_str_mv | 10.1016/j.actatropica.2018.03.016 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2015412068</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0001706X17313517</els_id><sourcerecordid>2015412068</sourcerecordid><originalsourceid>FETCH-LOGICAL-c377t-cca18ba5ee4a80c9a715009a4f728f3f408758fad0c39474af78c1fbe4a030383</originalsourceid><addsrcrecordid>eNqNkMGO0zAQhi0EYrsLr4DMjUvC2E5qh9tSAYtUaS8guFlTZ6K6SuJgO6x4e1x1QRy52LLm-2fGH2OvBdQCxPbtqUaXMceweIe1BGFqUHWpPGEbYbSqtrJtnrINAIhKw_b7FbtO6VReUrfyObuSXduCNHLDjnu_hBQmHDlOyzFkit75mb_nORLmiebMw8Dvx55_C7Gcbs04U1gTx7nn0-pCKtmRfDpOOHtMPr3jt3z0pRPmNRKP9NPTwwv2bMAx0cvH-4Z9_fjhy-6u2t9_-ry73VdOaZ0r51CYA7ZEDRpwHWrRAnTYDFqaQQ0NGN2aAXtwqmt0g4M2TgyHgoMCZdQNe3Ppu8TwY6WU7eSTo3G8bG2LrbYRErZntLugLoaUIg12iX7C-MsKsGfR9mT_EX2OGgvKlkrJvnocsx4m6v8m_5gtwO4CUPlsERBtcp5mR72P5LLtg_-PMb8BJyWW3Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2015412068</pqid></control><display><type>article</type><title>Liposomal amphotericin B treatment of Old World cutaneous and mucosal leishmaniasis: A literature review</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Mosimann, Vincent ; Neumayr, Andreas ; Paris, Daniel H. ; Blum, Johannes</creator><creatorcontrib>Mosimann, Vincent ; Neumayr, Andreas ; Paris, Daniel H. ; Blum, Johannes</creatorcontrib><description>Old World cutaneous and mucosal leishmaniasis is a potentially serious disease. Systemic treatment approaches with pentavalent antimonials, liposomal amphotericin B, fluconazole and miltefosine are increasingly used despite the absence of supportive evidence − to date, no prospective clinical trials have been conducted for systemic treatment of these diseases.
We performed a literature search to delineate the contemporary evidence for the use of liposomal amphotericin B, and found that although cure rates of 17/20 (85%) were achieved in immune competent patients with Old World cutaneous leishmaniasis and cure rates of 10/13 (77%) for Old World mucosal leishmaniasis due to L. infantum, the available data is highly limited with high variation in total treatment dosages. The presented findings reflect a lack of consensus on the optimal treatment dosage and on the schedule of application.</description><identifier>ISSN: 0001-706X</identifier><identifier>EISSN: 1873-6254</identifier><identifier>DOI: 10.1016/j.actatropica.2018.03.016</identifier><identifier>PMID: 29550282</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Amphotericin B - therapeutic use ; Antiprotozoal Agents - therapeutic use ; Cutaneous leishmaniasis ; Humans ; Leishmaniasis, Mucocutaneous - drug therapy ; Liposomal amphotericin B ; Mucosal leishmaniasis ; Old World leishmaniasis ; Systemic treatment ; Treatment Outcome</subject><ispartof>Acta tropica, 2018-06, Vol.182, p.246-250</ispartof><rights>2018 Elsevier B.V.</rights><rights>Copyright © 2018 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c377t-cca18ba5ee4a80c9a715009a4f728f3f408758fad0c39474af78c1fbe4a030383</citedby><cites>FETCH-LOGICAL-c377t-cca18ba5ee4a80c9a715009a4f728f3f408758fad0c39474af78c1fbe4a030383</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.actatropica.2018.03.016$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,778,782,3539,27907,27908,45978</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29550282$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mosimann, Vincent</creatorcontrib><creatorcontrib>Neumayr, Andreas</creatorcontrib><creatorcontrib>Paris, Daniel H.</creatorcontrib><creatorcontrib>Blum, Johannes</creatorcontrib><title>Liposomal amphotericin B treatment of Old World cutaneous and mucosal leishmaniasis: A literature review</title><title>Acta tropica</title><addtitle>Acta Trop</addtitle><description>Old World cutaneous and mucosal leishmaniasis is a potentially serious disease. Systemic treatment approaches with pentavalent antimonials, liposomal amphotericin B, fluconazole and miltefosine are increasingly used despite the absence of supportive evidence − to date, no prospective clinical trials have been conducted for systemic treatment of these diseases.
We performed a literature search to delineate the contemporary evidence for the use of liposomal amphotericin B, and found that although cure rates of 17/20 (85%) were achieved in immune competent patients with Old World cutaneous leishmaniasis and cure rates of 10/13 (77%) for Old World mucosal leishmaniasis due to L. infantum, the available data is highly limited with high variation in total treatment dosages. The presented findings reflect a lack of consensus on the optimal treatment dosage and on the schedule of application.</description><subject>Amphotericin B - therapeutic use</subject><subject>Antiprotozoal Agents - therapeutic use</subject><subject>Cutaneous leishmaniasis</subject><subject>Humans</subject><subject>Leishmaniasis, Mucocutaneous - drug therapy</subject><subject>Liposomal amphotericin B</subject><subject>Mucosal leishmaniasis</subject><subject>Old World leishmaniasis</subject><subject>Systemic treatment</subject><subject>Treatment Outcome</subject><issn>0001-706X</issn><issn>1873-6254</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkMGO0zAQhi0EYrsLr4DMjUvC2E5qh9tSAYtUaS8guFlTZ6K6SuJgO6x4e1x1QRy52LLm-2fGH2OvBdQCxPbtqUaXMceweIe1BGFqUHWpPGEbYbSqtrJtnrINAIhKw_b7FbtO6VReUrfyObuSXduCNHLDjnu_hBQmHDlOyzFkit75mb_nORLmiebMw8Dvx55_C7Gcbs04U1gTx7nn0-pCKtmRfDpOOHtMPr3jt3z0pRPmNRKP9NPTwwv2bMAx0cvH-4Z9_fjhy-6u2t9_-ry73VdOaZ0r51CYA7ZEDRpwHWrRAnTYDFqaQQ0NGN2aAXtwqmt0g4M2TgyHgoMCZdQNe3Ppu8TwY6WU7eSTo3G8bG2LrbYRErZntLugLoaUIg12iX7C-MsKsGfR9mT_EX2OGgvKlkrJvnocsx4m6v8m_5gtwO4CUPlsERBtcp5mR72P5LLtg_-PMb8BJyWW3Q</recordid><startdate>201806</startdate><enddate>201806</enddate><creator>Mosimann, Vincent</creator><creator>Neumayr, Andreas</creator><creator>Paris, Daniel H.</creator><creator>Blum, Johannes</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201806</creationdate><title>Liposomal amphotericin B treatment of Old World cutaneous and mucosal leishmaniasis: A literature review</title><author>Mosimann, Vincent ; Neumayr, Andreas ; Paris, Daniel H. ; Blum, Johannes</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c377t-cca18ba5ee4a80c9a715009a4f728f3f408758fad0c39474af78c1fbe4a030383</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Amphotericin B - therapeutic use</topic><topic>Antiprotozoal Agents - therapeutic use</topic><topic>Cutaneous leishmaniasis</topic><topic>Humans</topic><topic>Leishmaniasis, Mucocutaneous - drug therapy</topic><topic>Liposomal amphotericin B</topic><topic>Mucosal leishmaniasis</topic><topic>Old World leishmaniasis</topic><topic>Systemic treatment</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mosimann, Vincent</creatorcontrib><creatorcontrib>Neumayr, Andreas</creatorcontrib><creatorcontrib>Paris, Daniel H.</creatorcontrib><creatorcontrib>Blum, Johannes</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Acta tropica</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mosimann, Vincent</au><au>Neumayr, Andreas</au><au>Paris, Daniel H.</au><au>Blum, Johannes</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Liposomal amphotericin B treatment of Old World cutaneous and mucosal leishmaniasis: A literature review</atitle><jtitle>Acta tropica</jtitle><addtitle>Acta Trop</addtitle><date>2018-06</date><risdate>2018</risdate><volume>182</volume><spage>246</spage><epage>250</epage><pages>246-250</pages><issn>0001-706X</issn><eissn>1873-6254</eissn><abstract>Old World cutaneous and mucosal leishmaniasis is a potentially serious disease. Systemic treatment approaches with pentavalent antimonials, liposomal amphotericin B, fluconazole and miltefosine are increasingly used despite the absence of supportive evidence − to date, no prospective clinical trials have been conducted for systemic treatment of these diseases.
We performed a literature search to delineate the contemporary evidence for the use of liposomal amphotericin B, and found that although cure rates of 17/20 (85%) were achieved in immune competent patients with Old World cutaneous leishmaniasis and cure rates of 10/13 (77%) for Old World mucosal leishmaniasis due to L. infantum, the available data is highly limited with high variation in total treatment dosages. The presented findings reflect a lack of consensus on the optimal treatment dosage and on the schedule of application.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>29550282</pmid><doi>10.1016/j.actatropica.2018.03.016</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0001-706X |
| ispartof | Acta tropica, 2018-06, Vol.182, p.246-250 |
| issn | 0001-706X 1873-6254 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2015412068 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Amphotericin B - therapeutic use Antiprotozoal Agents - therapeutic use Cutaneous leishmaniasis Humans Leishmaniasis, Mucocutaneous - drug therapy Liposomal amphotericin B Mucosal leishmaniasis Old World leishmaniasis Systemic treatment Treatment Outcome |
| title | Liposomal amphotericin B treatment of Old World cutaneous and mucosal leishmaniasis: A literature review |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T00%3A43%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Liposomal%20amphotericin%20B%20treatment%20of%20Old%20World%20cutaneous%20and%20mucosal%20leishmaniasis:%20A%20literature%20review&rft.jtitle=Acta%20tropica&rft.au=Mosimann,%20Vincent&rft.date=2018-06&rft.volume=182&rft.spage=246&rft.epage=250&rft.pages=246-250&rft.issn=0001-706X&rft.eissn=1873-6254&rft_id=info:doi/10.1016/j.actatropica.2018.03.016&rft_dat=%3Cproquest_cross%3E2015412068%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2015412068&rft_id=info:pmid/29550282&rft_els_id=S0001706X17313517&rfr_iscdi=true |